CMMB Projected Dividend Yield

ADS (Sponsored)/Chemomab Therapeutics Ltd ( NASDAQ : CMMB )

Chemomab Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of targeted therapies to treat cancer. Co. is developing small-molecule pan-RAS inhibitors and inhibitors of phosphodiesterase (PDE10) and the ß-catenin pathway. Co.'s pan-RAS program has identified indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition. Co.'s PDE10/ß-catenin program has identified small molecules that inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models.

21 YEAR PERFORMANCE RESULTS